946 related articles for article (PubMed ID: 11358156)
21. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
22. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
23. [Prophylaxis for deep vein thrombosis with low molecular weight heparin following hip and knee surgery].
Li XL; Lu WJ; Yu NS
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2001 Jan; 15(1):39-41. PubMed ID: 12563929
[TBL] [Abstract][Full Text] [Related]
24. Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients.
Dahl OE; Gudmundsen TE; Bjørnarå BT; Solheim DM
Acta Orthop Scand; 2003 Jun; 74(3):299-304. PubMed ID: 12899550
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
26. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
27. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
28. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Lynd LD; Goeree R; Crowther MA; O'Brien BJ
Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
Själander A; Jansson JH; Bergqvist D; Eriksson H; Carlberg B; Svensson P
J Intern Med; 2008 Jan; 263(1):52-60. PubMed ID: 18088252
[TBL] [Abstract][Full Text] [Related]
30. DVT prophylaxis: better living through chemistry: affirms.
Pellegrini VD
Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
[TBL] [Abstract][Full Text] [Related]
31. [Low-molecular-weight heparin for preventing deep-vein thrombosis after total joint arthroplasty].
Yang G; Lu H; Gao J; Kou B; Yuan Y; Xu B
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):25-7. PubMed ID: 11831980
[TBL] [Abstract][Full Text] [Related]
32. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
33. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
35. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty.
Colwell CW
Orthopedics; 2009 Dec; 32(12 Suppl):67-73. PubMed ID: 20201479
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Brookenthal KR; Freedman KB; Lotke PA; Fitzgerald RH; Lonner JH
J Arthroplasty; 2001 Apr; 16(3):293-300. PubMed ID: 11307125
[TBL] [Abstract][Full Text] [Related]
37. Prevention of venous thromboembolism in high-risk surgical and medical patients.
Prandoni P; Sabbion P; Tanduo C; Errigo G; Zanon E; Bernardi E
Semin Vasc Med; 2001; 1(1):61-70. PubMed ID: 15199515
[TBL] [Abstract][Full Text] [Related]
38. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
39. Preventing DVT following total knee replacement: a review of recent clinical trials.
Fitzgerald RH
Orthopedics; 1995 Jul; 18 Suppl():10-1. PubMed ID: 7479418
[TBL] [Abstract][Full Text] [Related]
40. High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.
Kerr J; Linkins LA
Thromb Haemost; 2010 Jan; 103(1):123-8. PubMed ID: 20062935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
